The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients.
Blood Adv
; 7(5): 856-865, 2023 03 14.
Article
in En
| MEDLINE
| ID: mdl-36350752
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cytomegalovirus Infections
/
Hematopoietic Stem Cell Transplantation
Type of study:
Etiology_studies
/
Risk_factors_studies
Limits:
Adult
/
Humans
Language:
En
Journal:
Blood Adv
Year:
2023
Document type:
Article
Affiliation country:
Francia
Country of publication:
Estados Unidos